Current list of finished dosage formulations open for global market distribution and technology transfer. Read More

Current list of Unibest's innovative drug assets open for global licensing, co-developement and/or NewCo. Read More

This week, there are 6 drugs in the patent and exclusivity list. They are: - NOVARTIS PHARMACEUTICALS CORP's TAFINLAR, containing active ingredient DABRAFENIB MESYLATE - NOVARTIS PHARMACEUTICALS CORP's MEKINIST, containing active ingredient TRAMETINIB DIMETHYL SULFOXIDE - COLLEGIUM PHARMACEUTICAL INC's XTAMPZA ER, containing active ingredient OXYCODONE - ELI LILLY AND CO's OLUMIANT, containing active ingredient BARICITINIB - MEDICINES DEVELOPMENT FOR GLOBAL HEALTH's MOXIDECTIN, containing active ingredient MOXIDECTIN - JAZZ PHARMACEUTICALS IRELAND LTD's ZEPZELCA, containing active ingredient LURBINECTEDIN Read More

This week, there are 5 drugs in the patent and exclusivity list. They are: - PARATEK PHARMACEUTICALS INC's NUZYRA, containing active ingredient OMADACYCLINE TOSYLATE - SANDOZ INC's CIPRODEX, containing active ingredient CIPROFLOXACIN; DEXAMETHASONE - BRAEBURN INC's BRIXADI, containing active ingredient BUPRENORPHINE - INSMED INC's ARIKAYCE KIT, containing active ingredient AMIKACIN SULFATE - ABBVIE INC's VENCLEXTA, containing active ingredient VENETOCLAX Read More

Query Drug：TirzepatideQuery Time：2025-05-29 16:35:52*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Read More

EpimAb Biotherapeutics has successfully implemented the NewCo model through two significant deals in 2024-2025: licensing EMB-06 to Vignette Bio and a T-cell engaging molecule to Juri Biosciences. Read More

This article explores the intersection of virology and oncology, examining how scientists harness viruses' natural abilities to combat cancer. Unibest is pleased to present an oncolytic virus asset, currently in Phase II trials, that is open for global licensing and co-development opportunities. Read More

Obesity is a global health crisis affecting over 650 million people worldwide. But there's hope on the horizon. Recent breakthroughs in understanding how our gut and pancreatic hormones regulate appetite and blood sugar have led to the development of exciting new medicines to treat obesity and relat Read More

This week, there are 11 drugs in the patent and exclusivity list. They are: - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's SPIRIVA RESPIMAT, containing active ingredient TIOTROPIUM BROMIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's COMBIVENT RESPIMAT, containing active ingredient ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's STIOLTO RESPIMAT, containing active ingredient OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's STRIVERDI RESPIMAT, containing active ingredient OLODATEROL HYDROCHLORIDE - ALNYLAM PHARMACEUTICALS INC's ONPATTRO, containing active ingredient PATISIRAN SODIUM - ACROTECH BIOPHARMA INC's FOLOTYN, containing active ingredient PRALATREXATE - SUN PHARMACEUTICAL INDUSTRIES LTD's WINLEVI, containing active ingredient CLASCOTERONE - SALIX PHARMACEUTICALS INC's XIFAXAN, containing active ingredient RIFAXIMIN - FRESENIUS KABI USA LLC's DIPRIVAN, containing active ingredient PROPOFOL Read More